Antibody & antigen supply
Ended Awarded Last action
- Contract number
- HT942525F0237
- Awardee
-
Mapp Biopharmaceutical, Inc. UEI M9V9QTHR1H28
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $110,500
Award facts
- Opportunity
-
- HT942525R0047 Solicitation number
- Contract value 100% obligated
- $110,500.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325413 In-Vitro Diagnostic Substance Manufacturing
- Set-aside
- No set-aside
- Competition
- Not Competed under SAP Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- San Diego, CA 92121, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $110,500 |
About this award
The Defense Health Agency awarded a $110.5 million firm fixed-price delivery order to Mapp Biopharmaceutical, Inc., a San Diego-based biotechnology company specializing in antibody-based therapeutics and medical countermeasures. The delivery order, awarded on June 6, 2025, with completion scheduled for December 4, 2025, calls for the supply of monoclonal antibodies and viral recombinant antigens. No set-aside designation was used in this award. This delivery order is issued under Mapp's broader indefinite delivery contract with the Defense Health Agency, valued at $2 million and effective through May 31, 2030, which provides flexible procurement of antibody and antigen materials to support military medical preparedness and national health security requirements.
Mapp Biopharmaceutical has established itself as a critical federal partner since its registration in 2005, with a substantial portfolio exceeding $1.2 billion in federal contract and grant awards. The company's core expertise in immunotherapy development and infectious disease countermeasures aligns directly with the Defense Health Agency's medical readiness mission. Beyond this delivery order, Mapp maintains several major contracts with federal agencies, including a $906.65 million cost-plus-fixed-fee contract with the Office of the Assistant Secretary for Preparedness and Response for procurement of therapeutics targeting Ebola, Sudan, and Marburg viruses, and multiple federal grants supporting development of monoclonal antibody products for respiratory syncytial virus and dengue. This award reflects the agency's continued reliance on Mapp's capabilities to ensure availability of critical biological materials.
Quick answers
Who was awarded contract HT942525F0237?
HT942525F0237 was awarded to Mapp Biopharmaceutical, Inc. by Defense Health Agency (Department of Defense) on June 6, 2025.
How much is contract HT942525F0237 worth?
The government has obligated $110,500 on HT942525F0237.
Is contract HT942525F0237 an order under another contract?
Yes. HT942525F0237 is a delivery order under HT942525D0009, an indefinite delivery contract.
Was contract HT942525F0237 competed?
The extent of competition for HT942525F0237 was not competed under sap.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award